# Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

> **NCT04047186** · PHASE2 · COMPLETED · sponsor: **XiangNing Fu** · enrollment: 12 (actual)

## Conditions studied

- Multiple Pulmonary Nodules

## Interventions

- **DRUG:** Tislelizumab Injection

## Key facts

- **NCT ID:** NCT04047186
- **Lead sponsor:** XiangNing Fu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-05-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047186, "Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04047186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*